Introduction
Visual acuity, the most widely diffuse measure of visual function, has shown poor degree of correlation with both qualitative (fluorescein angiography) and quantitative (optical coherence tomography [OCT] ) assessments of macular morphology [1] [2] [3] . Also other less commonly used measures of function, such as contrast sensitivity, microperimetry, near acuity and reading speed, did not show better relationships with morphological features compared with visual acuity [4] [5] [6] [7] . Therefore, to date, there are still no simple and reproducible functional tests that reflect the morphological state of the macula in patients affected with diseases like exudative age-related macular degeneration (AMD).
The Prospective OCT Imaging of Patients with Neovascular AMD Treated with intraOcular Ranibizumab (PrONTO) Study 8 showed that monthly visits, for both functional and morphological monitoring, are necessary in patients undergoing intravitreal anti-VEGF treatment for AMD, in order to take optimal re-treatment decisions 9 . However, based on clinical experience, it seems that in such patients, visual acuity changes would lag behind morphological worsening. Therefore, availability of an objective and easily performed functional test, which well correlates with macular morphology, would be extremely helpful in the clinic setting.
Preferential Hyperacuity Perimetry (Foresee PHP®, Notal Vision, Israel) has recently gained popularity as a device for monitoring visual distortion, and has been used to localize functional deficits in the central 14 degrees of visual field in patients with AMD 10, 11 .
Since 2005 Preferential Hyperacuity Perimeter has been proposed as a tool to detect CNV 10 . Results of a multicenter clinical trial confirmed the usefulness of Preferential
Hyperacuity Perimeter for detection of AMD 11 . Recently, the home version of the Preferential Hyperacuity Perimeter, the ForeseeHome, which is based on a technology that is similar to the Foresee PHP, has shown a good sensitivity and specificity in PHP in exudative AMD 6 discriminating between patients with newly diagnosed CNV and intermediate AMD 12 .
Preferential Hyperacuity Perimeter has also been suggested as a tool for monitoring the therapeutic response to photodynamic therapy and anti-VEGF treatment in neovascular AMD 13, 14 .
In this pilot study we investigated the ability of Foresee Preferential Hyperacuity Perimetry (PHP) in assessing responsiveness to ranibizumab therapy. With this aim, we analyzed the short-term functional and morphological fluctuations after intraviteal ranibizumab injection for exudative AMD.
Methods
Fourteen consecutive patients with exudative AMD in one eye received an intravitreal injection of ranibizumab (0.05 ml/0.5mg) at the University Eye Clinic of Creteil. In this prospective pilot study, we investigated the ability of PHP in assessing responsiveness to ranibizumab therapy. Before administration of ranibizumab, patients were informed about the experimental aspects of the study and the need for repeating several examinations at each scheduled follow-up visit. Criteria for inclusion were: 1) age Since the normality assumption was not satisfied for the measurement variables, we have used nonparametric tests: the Spearman correlation was evaluated, in order to examine the degree of correlation between OCT average parameters change, LogMAR BCVA average change and PHP test score average change. Differences between baseline and 1 month visits were compared using Wilcoxon signed rank test.
For the question of whether an increase in PHP test score within the individual was associated with an increase in OCT combined parameter, we had removed the differences between subjects and look only at changes within by multiple regression method, using the OCT data as the outcome variable and the PHP test score and the subject as the predictor variables. Subject is treated as a categorical factor using dummy variables (15) .
In order to investigate the relative change vs baseline examination, all parameters were collected to a table and classified as "better", "worse" or "same" with respect to BCVA (LogMAR change >0.1), "combined OCT parameter" (change > 10 microns) and PHP test score (change > 15).
An analysis of variance for repeated measures (ANOVA) was performed in order to determine the effect of time on the different measurements. The chosen level of statistical significance was p < 0.05.
Results
Fourteen treatment naive eyes of 14 consecutive Patients with exudative AMD met the inclusion criteria and were included in the analysis. Demographic and clinical data for these patients are summarized in table 1. The mean age was 83±6.2 years, and the gender distribution was 78% women. All included patients presented at each scheduled follow-up visit, and underwent all examinations except for 3 patients who missed the PHP examination at the last follow-up visit (1 month after the intravitreal ranibizumab injection).
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Therefore, 67 out of the 70 scheduled PHP tests were performed at 1 month. All PHP tests made in this study except 3 (4%) showed a good a reliability score.
In table 2 The natural dynamics, both anatomical and functional, within the first month following intravitreal ranibizumab injection are presented in table 2 and figure 1 (case presentation).
It is notable that there was an improvement in all parameters, and that for BCVA and OCT the majority of significant changes happened within 1 day to 1 week after treatment The correlation coefficient between OCT measurements and PHP score within subjects was 0.51 (p<0.05) (which indicates that an increase in OCT combined parameter was associated with an increase in PHP test score within the individual).
An analysis of variance for repeated measures (ANOVA) showed a negative significant impact of treatment (improvement over time) on BCVA logMAR, OCT combined parameter, and PHP test score (Type III tests of fixed effects, p<0.05). The time points with the highest impact on the model were 1 week and 1month after treatment for both BCVA and OCT, and the 1 week time point for the PHP (p<0.05 for these time points).
Categorized functional and morphological changes ("better", "worse" or "same"), for each eye, at each time-point relative to baseline, are reported in table 3.
Discussion
In this prospective study we investigated the ability of (less than half of one ETDRS line) did not correlate with OCT changes. However, it is worth noting that the authors did not set out to specifically test whether PHP could help with assessing responsiveness to ranibizumab therapy. Conversely, in the current study, we included only treatment naive eyes, which were regularly followed (prospectively) and re-examined at several fixed time-points (67 BCVA-PHP tests-retests), during a limited 1-month period.
The strong correlation here reported between functional PHP metamorphopsia changes and morphological OCT changes is even more important considering the population Our study has several limitations. All patients underwent a single injection of ranibizumab.
The sample size was small, and 3 patients missed the PHP examination at 1 month; also, despite 67 PHP tests were performed over 1 month, follow-up is short, and no definitive conclusion can be drawn. In addition, even though we found a significant correlation between progressive reduction of morphological signs of disease activity (OCT parameters), and functional improvements as evaluated by PHP, this applied to newly diagnosed active CNVs; therefore, we actually have no data on such a correlation, in eyes with CNV evolving towards quiescent inactive fibro-atrophic lesions, as it may happen following a certain number of repeated anti-VEGF treatments. Finally, we did not perform other tests (such as NEI VFQ -25 and microperimetry), which would have been useful to PHP in exudative AMD 14 better characterize the short-term functional and morphological fluctuations in these patients.
In conclusion, we found that functional improvement in metamorphopsia test score after intravitreal ranibizumab injection, well correlates with improvement in several OCT parameters reflecting the disease activity. Our findings suggest that PHP may be considered an useful tool to monitor response to anti-VEGF treatment in patients with 
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